

Title (en)

ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS

Title (de)

ANTI-ALPHA-V-INTEGRIN-ANTIKÖRPER ZUR BEHANDLUNG VON FIBROSE UND/ODER FIBROTISCHEN ERKRANKUNGEN

Title (fr)

ANTICORPS DE L'INTÉGRINE ANTI-ALPHA-V POUR LE TRAITEMENT DE LA FIBROSE ET/OU DE TROUBLES FIBROTQUES

Publication

EP 3380520 A2 20181003 (EN)

Application

EP 16808567 A 20161122

Priority

- US 201562258626 P 20151123
- EP 16164879 A 20160412
- EP 2016001970 W 20161122

Abstract (en)

[origin: WO2017088974A2] The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de- immunized monoclonal antibody targeting av-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.

IPC 8 full level

C07K 16/28 (2006.01)

CPC (source: EA EP KR)

A61K 31/343 (2013.01 - KR); **A61K 39/395** (2013.01 - EA EP KR); **A61K 45/06** (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/2839** (2013.01 - EA EP KR); **C12Q 1/25** (2013.01 - EA EP); **C12Q 1/6883** (2013.01 - KR); **C12Q 3/00** (2013.01 - EA EP); **G01N 33/54366** (2013.01 - EA EP); **G01N 33/6893** (2013.01 - KR); **A61K 2039/505** (2013.01 - EA EP KR); **A61K 2300/00** (2013.01 - KR); **C07K 2317/73** (2013.01 - EA EP KR); **C07K 2317/76** (2013.01 - EA EP KR); **C12Q 2600/158** (2013.01 - KR)

Citation (search report)

See references of WO 2017088974A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2017088974 A2 20170601; **WO 2017088974 A3 20170713**; AU 2016360661 A1 20180705; AU 2016360661 B2 20231214; BR 112018010337 A2 20181204; CA 3005764 A1 20170601; CN 108473582 A 20180831; EA 201891204 A1 20190329; EP 3380520 A2 20181003; KR 20180081617 A 20180716; MX 2018006269 A 20180905; SG 11201804243Q A 20180628; TW 201720843 A 20170616

DOCDB simple family (application)

EP 2016001970 W 20161122; AU 2016360661 A 20161122; BR 112018010337 A 20161122; CA 3005764 A 20161122; CN 201680077086 A 20161122; EA 201891204 A 20161122; EP 16808567 A 20161122; KR 20187017898 A 20161122; MX 2018006269 A 20161122; SG 11201804243Q A 20161122; TW 105138308 A 20161122